Plastic and reconstructive surgery
It belongs to a new generation of incretin-based compounds often called triple agonists because of their ability to simultaneously activate three distinct metabolic receptors: the glucose-dependent insulinotropic polypeptide receptor (GIPR), the glucagon-like peptide-1 receptor (GLP-1R), and the glucagon receptor (GCGR)
Significant results highlight the effectiveness of higher doses (e.g., 70.3 lbs loss) for substantial long-term weight control
Roberto Gradini, Sapienza University of Rome, Italy
Without priming, the first injection may deliver incomplete medication or allow air bubbles to enter subcutaneous tissue
For patients who experience significant nausea or gastrointestinal upset on single-agent therapy, the GLP-Squared Injection ($289/mo) combines semaglutide and tirzepatide at complementary doses